Abstract
Background The world’s governments have agreed both global and national actions to address the challenge of antimicrobial resistance. This raises the importance of understanding to what degree national action so far has been effective. Answering this question is challenged by variation in data availability and quality as well as disruptive events such as the COVID-19 pandemic. We investigate the association between a survey of self-reported action based on the first Global Database for Tracking Antimicrobial Resistance (TrACSS) survey and trends in multiple indicators related to the DPSEEA framework leading up to the survey.
Methods and findings We apply regression methods across 73 countries between actions in 2016 and the trend in indicators of health system development (drivers), antibiotic use (pressures, ABU), absolute rates of resistance (state, ABR) and relative rates of resistance (exposure, Drug Resistance Index, DRI) from 2000 to 2016. We find that action is consistently associated with improved linear and categorical trend in health systems, ABU, ABR and DRI. Reductions are associated with relatively high levels of action (0-4) for ABU (median 2.8, 25-75% quartile 2.6-3.3), ABR (3.0, 2.4-3.4), and DRI (3.5, 3.1-3.6). These associations are robust to the inclusion of other contextual factors such as health system and socio-economic status, human population density, animal production and climate. Since 2016, a majority of both Low-Middle Income Countries (LMICs) and High-Income Countries (HICs) report increased action on repeated questions, while one third of countries report reduced action. The main limitations in interpretation are heterogeneity in data availability and the recency of action.
Conclusions Our findings highlight the importance of national action to address the domestic situation related to antibiotic resistance and indicate the value of both incremental changes in reducing adverse outcomes and the need for high levels of action in delivering improvements.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge funding from the Erling-Persson Family Foundation (L.N.T., P.S.J), the European Union (ERC, INFLUX, 101039376, P.S.J.), the IKEA Foundation (P.S.J.), the Marianne and Marcus Wallenberg Foundation (P.S.J) and the Uppsala Antibiotic Centre (UAC, L.N.T.). The funders had no role in the design, analysis, or writing of this paper. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authorities can be held responsible for them. We thank all participants of the SESYNC Living with Resistance pursuit for their participation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced willlbe available online via Github.
